As you may know, infant that are born premature are at an increased risk for a number of heart and lung disorders including bronchopulmonary dysplasia. This disorder can be fatal and is generally treated with oxygen for many months. It can result in chronic lung damage.
But researchers at the Cincinnati Children’s Hospital Medical Center are in the process of developing a new treatment which holds out hope for a more effective treatment of this disorder. The research has now received a half-million dollar grant from the CincyTech and Cincinnati Children’s Tomorrow Fund.
The funds come from a public-private partnership that is helping high-tech startups in Southwest Ohio. An executive from the funding group said that bronchopulmonary dysplasia affects approximately 5,000 to 10,000 infants each year.
The treatment involves the use of a new type of protein. It is hoped that this new treatment can substantially improve lung function in premature infants that suffer from bronchopulmonary dysplasia. It appears to reduce the lung inflammations associated with the disorder.
The $500,000 investment is expected to help the researchers apply for approval for use of the treatment from the U.S. Food and Drug Administration sometime in the next 15 months.
Last week in this space we talked about a new ‘cool therapy’ treatment. As you can see the field of treatment for care of infants with health problems is developing rapidly. Health problems that might have meant a death sentence just a few years ago may now be regularly treated using these new techniques and pharmaceuticals.
Source: Cincinati.com “$500K helps startup develop lung treatment” Mike Boyer, June 3, 2011